Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinas...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Med Oncol
Hlavní autoři: Rossi, Lorenzo, McCartney, Amelia, Risi, Emanuela, Malorni, Luca, Biganzoli, Laura, Di Leo, Angelo
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2018
Témata:
Editorial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6295674/
https://ncbi.nlm.nih.gov/pubmed/30574210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918815591
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky